.
Chemokines mediate their activities by binding to the receptors that comprise a subfamily of rhodopsinlike, 7-transmembrane (7TM) domain receptors (also called serpentine receptors), G protein-coupled receptors (GPCR); they signal mainly through Gi-type proteins 1 .
A general model for plasma membrane insertion of (7TM) proteins has been proposed, based on the distribution of conserved sequences and the known structure of rhodopsin. In this model, the receptor polypeptide is stitched into the membrane with the N-terminus extracellular domain, the C-terminus intracellular domain, and each of seven hydrophobic domains passing as α helices through the membrane 2 . This allows four extracellular, and four intracellular domains: a total of six loops (il-3 and el-3) connecting the seven (TM) domains, which form the (TM) core, and the free N-and C-termini 2 . The receptors have a single polypeptide chain and have 25-80 % of amino acid sequence identity to each other. These and other aspects of their structure indicate that chemokines and chemokine receptors each arose from common ancestors by repetitive gene duplication. Although chemokine receptors are similar to many GPCRs, they have unique structural motifs such as the amino acid sequence DRYLAIV in the second intracellular domain 3 . Chemokines have two main sites for interaction with their receptors: the first lies in the amino-terminal region and the second is located in the exposed loop of the backbone between the second and the third cysteine 4 . The receptor initially recognises the chemokine loop region, and this interaction is necessary for the correct presentation of the amino-terminal region, which is then essential for the receptor triggering.
The chemokine signalling network is astonishingly complex, however the primary task of each receptor is conceptually simple, to bind a chemokine and to relay its signal to a heterotrimetric guanine nucleotide-binding regulatory protein (Gαβγ protein). Agonist binding to the receptor catalyses the exchange of GTP for the GDP that is bound to the Gα subunit and induces a dissociation/reassociation cycle of the Gα and Gβγ subunits 5 . The GTP-bound Gα subunit and the Gβγ subunits then both independently activate downstream effectors such as adenylate cyclase, phospholipase Cβ, phosphatidylinositol-3-kinase and protein tyrosine kinases -allowing for cross-talk with the mitogen-activated protein kinase cascades (recently reviewed by Ward 6 et al., 1998). At present, 17 receptors have been identified. In agreement with the current chemokine nomenclature 7 , a name for a chemokine receptor starts with the abbreviation of its chemokine ligand subclass specificity (CC, CXC, XC, or CX3C), which is followed by "R" (for receptor) and then ends with a serial number. Thus, we have CCR1-10, CXCR1-5, XCR1 (the lymphotactin, XCL1, receptor), and CX3CR1 (the fractalkine, CX3CL1, receptor). The known chemokine receptors, together with their ligands and cell types for expression, are shown in the Table 1. The table also illustrates "shared binding specificity" between many ligands and receptors. This "promiscuity" is real because it involves high-affinity interactions. Thus, a single chemokine may bind to several receptors, whereas a single chemokine receptor may transduce signals for several chemokines. This is one of the most intriguing features of the chemokine superfamily and may reflect their ability to regulate many different leukocyte subpopulations, especially in complex microenvironments such as acute or chronic inflammatory responses.
Some of novel chemokine receptor belong to "orphan" receptors. These are proteins where the ligand had not been identified. Abbreviations for chemokines: BCA-1, B cell-attracting chemokine 1; BLC, B-lymphocyte chemoattractant; 6Ckine, six-Cysteine chemokine; ENA-78, epithelial-cell derived neutrophil activating protein 78; ELC, EBI-1 ligand chemokine; GCP-2, granulocyte chemoattractant protein 2; GRO, growth-related oncogene; HCC-2, hemofiltrate CC chemokine 2; I-309, inducible 309; IL-8, interleukin 8; IP-10, interferon-inducible protein 10; I-TAC, interferon-inducible T-cell α chemoattractant; LARC, liver and activationregulated chemokine; MCP, monocyte chemotactic protein; MDC, macrophage-derived chemokine; MIG, monokine induced by interferon gamma; MIP, macrophage inflammatory protein; NAP-2, neutrophil-activating peptide 2; SDF-1, stromal cell-derived factor 1; SLC, secondary lymphoid tissue chemokine; STCP-1, stimulated T cell chemotactic protein; RANTES, regulated on activation of normal T cell expressed and secreted; TARC, thymus and activation-regulated chemokine; TECK, thymus-expressed chemokine 
CHEMOKINE RECEPTOR -LIGAND INTERACTIONS: THE FOUR GENERAL CATEGORIES

Promiscuous receptors
The first class of chemokine receptors is that of the promiscuous receptor (Figure 1) . It is defined here as a receptor which will bind chemokines of either CXC or CC classes. There is, however, only one example of this receptor to date, the erythrocyte chemokine receptor, name DARC (Duffy antigen receptor for chemokines). This receptor is expressed on erythrocytes and endothelial cells, where it was originally defined serologically as the Duffy blood group antigen and later pathologically as the invasin for the malaria-causing protozoan Plasmodium vivax 10, 11 . Although DARC is structurally related to chemokine receptors it lacks the DRYLAIV motif in the second cytoplasmic loop, it is not coupled to heterotrimetric G-proteins and importantly does not elicit any detectable signal-transduction events 10, 11 . The biological role for DARC is, therefore, unclear; it has been proposed to act as a "sink" for chemokines, which keeps their circulating levels low 10, 11 .
Shared receptors
The second category is represented by the shared receptors, defined here as receptors which will bind to more than one chemokine within either the CXC or the CC class (Figure 1 ). There are three CXCR receptors (CXCR1-3), which bind to many of the CXC chemokines, and all CCR1-10 receptors, which bind to several of the CC chemokines.
Specific receptors
The third category is that of specific receptors, which seem to bind only one chemokine (Figure 1 ). These are the receptors such as XCR1 for lymphotactin (XCL1), CX3CR1 for fractalkine (CX3CL1), CXCR5 for BCA-1 (CXCL13), and CXCR4 for SDF-1 (CXCL12).
Virally encoded receptors
The fourth category of receptors are the virally encoded chemokine receptors ( Figure 1 ). Although chemokines and chemokine receptors probably evolved as antimicrobial factors, many are exploited by infectious agents to facilitate the infection. Certain herpesviruses encode pirated chemokine receptors, including US28 (used by human cytomegalovirus), and ECRF3 (used by Herpesvirus saimiri) 12, 13 . US28 binds the CC chemokine MIP-1α (CCL3), MIP-1β (CCL4), RANTES (CCL5) and MCP-1 (CCL2) with similar affinity 12 . ECRF3 is selective for the CXC chemokines IL-8 (CXCL8), GROα (CXCL1) and NAP-2 (CXCL7) 13 . US28 and ECRF3 functions have not been identified yet. Human cytomegalovirus and Herpesvirus saimiri could use chemokine receptors to control viral replication by regulating cell cycle progression of the host cell, or by inhibition apoptosis of the host cell 12, 13 . 
CHEMOKINE RECEPTORS AS MARKERS OF T LYMPHOCYTE DIFFERENTIATION
Immune-mediated diseases can be classified as either Th1 (T helper 1) or Th2 (T helper 2) immunopathologies depending on the spectrum of cytokines produced by activated Th cells. Th1 cells produce mainly Interleukin (IL)-2, IFN-γ and IL-12 whereas Th2 cells secrete IL-4, IL-5, IL-10 and IL-13 15 . Th1 cells are the major players in the inflammation characterised by activated T cells and macrophages, and have been associated with diseases such as rheumatoid arthritis and delayed-type hypersensitivity reactions 9 . Th2 cells are involved in the responses leading to eosinophil and basophil recruitment and have therefore been implicated in the pathogenesis of allergic inflammatory diseases such as asthma and atopic dermatitis 16 .
Recently, it has been demonstrated that chemokine receptors are differentially expressed on naive Th1 and Th2 subsets, and their expression is modulated by cytokines. Naive T cells primarily express CXCR4 and thus are responsive to SDF-1 (CXCL12, stromal cellderived factor 1), a chemokine that has an important role in basal trafficking of naive T cells into lymphatic organs. Upon activation, T cells may express an array of chemokine receptors including CCR1, CCR2, CCR5, CXCR1 and CXCR4 17 . They thus become sensitive to inflammatory chemokines including MIP-1α (CCL3), MIP-1β (CCL4), MCP-3 (CCL7) and RANTES (CCL5), which are thought to mediate T-cell trafficking to secondary lymph node structures and sites of inflammation bacterial or viral infections IP-10 (CXCL10), Mig (CXCL9), IL-8 (CXCL8) and I-TAC (CXCL11) production correlates with the presence of CD4 + Th1 cells 17 . In contrast, during allergic inflammatory responses eotaxin (CCL11), RANTES (CCL5), MCP-2 (CCL8), MCP-3 (CCL7) and MCP-4 (CCL13) are induced and the majority of the CD4 + T lymphocytes are of the Th2-type phenotype 17 . Characterisation of chemokine receptor expression on T lymphocytes suggests that this may be explained by the expression of CXCR3 and CCR5 predominantly on CD4 + Th1 cells 18, 19, 20 , whereas CCR3, CCR4, CCR8 (and perhaps CCR7) are restricted to CD4 + Th2 cells 19, 20, 21 ; the following molecules -CXCR4 and CCR2, and possibly also CCR1 -are expressed equally on both Th1 and Th2 cells, suggesting that these receptors as opposed to polarised (Th1 vs Th2) immune responses 18, 19, 23 ( Figure 2 ). These observations suggest that chemokine receptors expression on T cells together with tissue-specific chemokine expression are important factors in controlling the composition of lymphocyte infiltrates in different types of inflammatory pathologies.
(T-tropic strains) 25, 26 and CCR5 is coreceptor for HIV-1 isolates that infect macrophages and activated T cells (M-topic strains) 27, 28 . The importance of chemokine receptors in the pathophysiology of HIV infection became apparent when it was discovered that in an individual who was homozygous for a 32 bp deletion in the human CCR5 gene (CCR5δ32 allele), a functional CCR5 protein cannot be synthesised, and such individuals are generally not found in HIV-1 positive cohorts 29, 30, 31 . Furthermore, in persons who are heterozygous for the mutation, the rate of progression of HIV-1 infection is slower than in those without the mutation 29 . CCR5δ32 appears to have originated in northeaster Europe, and it occurs with an average allelic frequency of 10 % in North American Caucasians; it is not found in native Asians and Africans. The frequency of the deletion mutation in the Czech population is no different from that in other European Caucasian populations 32 . Many other polymorphisms, relevant to HIV infection, have been described in chemokine receptor genes ( Table 2 ). Another much rarer mutation, CCR-m303 (which contains a premature stop codon at position 303) has also been reported to confer resistance to HIV-1 infection, and is presumed to act like δ32 33 . The other two affect the rate of disease progression but may not affect susceptibility to initial infection, and their mechanism us unclear. One of these polymorphisms caused a conservative amino acid change in CCR2 (V64I, substitution of valine for isoleucine in the first transmembrane domain) 34 and the other is single-nucleotide polymorphism in the CCR5 promoter (59029A/G), which has a particularly strong affect and is very common in all racial groups tested 35, 36 . Easterbrook 37 et al. studied effects on HIV disease progression of other polymorphisms in the promoter region of CCR5 (positions 59353 and 59402), and found that 59353 C allele was associated with a delayed progression.
CHEMOKINE RECEPTORS AND HIV INFECTION
Human Immodefficiency virus (HIV-1) is the aetiologic agent of AIDS which results from the destruction of CD4 + lymphocytes in infected individuals. The entry of HIV-1 into its targets cells is mediated by the viral envelope glycoproteins such as gp120, which binds the cellular receptor CD4, resulting in conformational change that exposes the V3 loop in gp120 and permits subsequent interaction with a chemokine receptor. The primary cellular receptor for all strains of HIV-1 is CD4 molecule 24 , but strain-specific chemokine receptors are required as coreceptors for fusion and entry 25 . CXCR4 is coreceptor for strains of HIV-1 that infect T-cell lines Abbreviations: -/-, homozygous for the given allele; +/-, heterozygous for the given allele; SNP, single nucleotide polymorphism; Del, deletion; R, HIV-1 resistance; DP, delayed progression to AIDS relative to other genotypes; ND, not determined adapted from the references no. 1 and 37
Fig. 2 The chemokine receptors as markers for T lymphocyte differentiation (adopted from the ref. 6).
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CHEMOKINE RECEPTOR (CCR2, CCR5, CXCR1 AND CXCR2) GENE POLYMORPHISMS IN OTHER DISEASE
Several studies have recently suggested association of certain chemokine receptor gene polymorphisms with other immunological diseases than HIV infection (Table 3).
Hall 38 et al. reported that individuals carrying the CCR5δ32 mutation are at reduced risk of asthma. This has not, however been confirmed in the Hungarian population, where CCR5δ32 mutation in non-asthmatic but atopic children did not indicate a reduced risk 39 . Petřek 40 et al. have shown an association between CC chemokine polymorphisms with pulmonary sarcoidosis in the Czech population. Their study has shown a decrease of the CCR2-64I allele, and a significant increase in the frequency of CCR5δ32 allele in patients with sarcoidosis, CCR5δ32 allele was associated with advanced disease. CC chemokine receptor polymorphisms should therefore be considered to be protective (CCR2-64I) or susceptibility (CCR5δ32) factors for the development of sarcoidosis. In agreement with the above findings, Hizawa 41 et al., have reported that CCR2 polymorphism (CCR2-64I) is associated with decreased susceptibility to sarcoidosis in Japanese population.
A role of CCR2 and CCR5 gene polymorphisms in other immune-mediated diseases, such as multiple sclerosis (MS) and insulin-dependent diabetes mellitus (IDDM) was not confirmed 42, 43 , however, a mutation in the CCR2 gene was postulated to possibly contribute to the susceptibility to the IDDM 43 . The studies of association CCR5δ32 with susceptibility to rheumatoid arthritis have yielded with quite conflicting results. Gómez-Reino 44 et al. suggested that a functional CCR5 receptor was required for the development of rheumatoid arthritis (RA) and this conclusion was based on the absence of the homozygous CCR5δ32 deletion in patients with RA. The findings of Cooke 45 et al. were opposite: they have found two patients with homozygous CCR5δ32 who had typical disease, and they concluded that blockade of CCR5 was unlikely to have therapeutic benefit. Another report on this topic by Mack 46 et al., showed that the number of CCR5-positive cells in the synovial fluid did not differ between the CCR5/CCR5 wild-type and the CCR5δ32/CCR5 heterozygous patients with RA. This finding suggests that a complete deficiency in the CCR5 receptor expression does not prevent the development of RA and other chemokine receptors (e.g., CCR2, CXCR3) may substitute for the CCR5 deficiency.
Renzoni 47 et al. described 4 novel polymorphisms in the CXCR1 and CXCR2 genes. In the CXCR1 gene a novel polymorphism at nucleotide +2607 was found, resulting in a conservative amino acid substitution from serine to threonine at the 276 amino acid residue of the CXCR1 protein. In the CXCR2 gene 3 novel polymorphisms at nucleotide +785 (C or T), +1208 (T or C), and +1440 (G or A) were identified, the first of which resulted in a silent codon change and the others were in the 3 untranslated area of exon. The authors 47 studied an association between these polymorphisms and systemic sclerosis (SSc) and cryptogenic fibrosing alveolitis (CFA) and have reported an association between two polymorphisms in the CXCR2 gene (CXCR2 +785 and CXCR2 +1208) and systemic sclerosis, independent of the presence of fibrosing alveolitis. This finding suggest a role for CXCR2 receptor in the pathogenesis of systemic sclerosis disease. No association was found between novel CXCR1 and CXCR2 polymorphisms and cryptogenic fibrosing alveolitis. Abbreviations: +, polymorphism is associated with disease; -, polymorphism is not associated with disease; CFA, cryptogenic fibrosing alveolitis; CCR5δ32, a 32-bp deletion in the CCR5 gene; CCR2-64I, a substitution mutation in the CCR2 gene; CXCR1 (+2607), polymorphism at nucleotide +2607 (G/C) in the CXCR1 gene; CXCR2 (+785), polymorphism at nucleotide +785 (C/T) in the CXCR2 gene; CXCR2 (+1208), polymorphism at nucleotide +1208 (T/C) in the CXCR2 gene; CXCR2 (+1440), polymorphism at nucleotide +1440 (G/A) in the CCR2 gene; IDDM, insulin-dependent diabetes mellitus; FASSc, systemic sclerosis with fibrosing alveolitis; NFASSc, systemic sclerosis without fibrosing alveolitis
KNOCKOUT MICE AND EXPRESSION LEVELS AS TOOLS FOR TARGET VALIDATION
Several chemokine and their receptors have been deleted in mice to address whether they a play a specific role in normal maintenance of the immune system or in diseased states where the immune balance is disturbed. There have already been some interesting results (Table 4) .
Deletion of the CXCR2 homologue in mice caused impaired neutrophil recruitment upon infection, suggesting that CXCR2 antagonists may be useful in managing tissue damage during acute lung inflammation or sepsis 48 . Deletion of either CXCR4 or its ligand SDF-1 (CXCL12) impaired bone marrow myelopoiesis, B cell lymphopoiesis, cerebellar development and gastric vascularization, and was lethal 50, 51, 52 . Gutierrez-Ramos 65 studied of the in vivo role of CXCR4 and its ligand, SDF-1 (CXCL12), during allergic airway disease (AAD). This study has been limited by the fact that transgenic mice that have been made deficient in either molecule die early in life. The author 65 presents data supporting that lungs from asthmatic patients as well as inflamed lung of mice subjected to a model of AAD show modulation of CXCR4 mRNA and protein expression during diseases. The blockade of CXCR4 in vitro lead to reduce the migration of both eosinophils and lymphocytes to the lung (BAL fluid and lung interstitium) by 50 and 60%, respectively, indicating that CXCR4-mediated signals contribute to lung inflammation during allergic processes. CXCR4 and SDF-1 (CXCL12) have a critical role during AAD and the potential relevance of this receptor and its ligand in other inflammatory processes 65 . BLR-1/CXCR5 knockout do not develop inguinal lymph nodes or B cell areas in secondary lymphoid tissues 53 . The chemokine receptor BLR-1/CXCR5 is the first G protein-coupled receptor involved in the regulation of B cell migration and localisation of these cells within specific anatomic compartments 53 . , and decreased the severity of symptoms in models of multiple sclerosis. CCR1 knockout also have reduced pancreatitis-associated pulmonary inflammation 55 . Deletion of CCR2 resulted in reduced monocyte and macrophage recruitment in response to inflammatory stimuli, and a decreased pathology in an atherosclerotic mouse model, suggesting a role for CCR2 antagonists in this disease 60 . Macrophage and T cell accumulation in autoimmune and degenerative disorders is associated mainly, but not exclusive, with CC chemokines. There are also appear to be important in allergic inflammation in diseases such as asthma, based on the local presence of eotaxin (CCL11), MCP-3 (CCL7) and RANTES (CCL5); and expression of their shared receptor, CCR3, on eosinophils, basophils and Th2 cells, which accumulate at sites of allergic inflammation 21, 66, 67 . In spite of the high level expression of CCR4 seen in vitro on Th2 polarised cells, in vivo, in an ovalbumin (OVA) model of inflammation (OVA induced lung inflammation, which is a predominantly Th2 driven disease), CCR4 does not appear to be required for development of a Th2 response 68 . Yet surprisingly, blockade of a CCR4 ligand, mouse MDC (CCL22), in the OVA model significantly reduces both bronchial hyperreactivity and leukocyte infiltration into the lung interstitium 68 . This suggests that there may be some compensatory mechanism for the loss of CCR4 in vivo or that a second receptor for MDC (CCL22) exists in mice 68 . CCR5 expression is enhanced in the course of in vitro Mycobacterium tuberculosis infection and during active pulmonary tuberculosis 69 . CCR5 deletion have enhanced delayed hypersensitivity reactions and increased humoral responses to cell-dependent antigenic challenge 61 . Consistent with the notion that the chemokine system supports host defense, CCR1 and CCR5 knockout mice have increased susceptibility to inoculation with Aspergillus fumigatus and Listeria monocytogenes, respectively 61 . However, neither these nor any of the other chemokine/receptor knockout have increased susceptibility to spontaneous infection, indicating that sufficient redundancy exists within the system for baseline host defense 1 . Thus therapeutic "anti-chemokines" that are eventually developed (none has reached clinical trials yet) may profit from the specifity that certain chemokine appear to demonstrate in the amplification of pathologic inflammation versus the redundancy that appears to characterise chemokine regulation of immune function Summarising the data from the different target validation approaches discussed above (monitoring expression levels, targeted gene disruption, use of blocking antibodies, modified chemokines) and tentatively infer pathogenic correlations relating various inflammatory diseases to particular chemokine receptors (Table 5) . 
CONCLUSIONS
The spectrum of chemokine and their receptors roles has expanded since the first comprehensive review on this topic 87 . Nowadays, detailed understanding of chemokine receptor structure and signalling suggests new treatment modes for immune-mediated disease. Therapeutic targeting of chemokines and their receptors represents extension of their traditional understanding as proinflammatory mediators 88 and has been already envisaged 89 . Moreover, recent suggestion that chemokine receptor gene polymorphism may play a role in susceptibility to immune disease, is a novel concept and brings new aspect to the complex field of chemokines and chemokine receptors.
